OpGen

OpGen Book Value per Share

The Book Value per Share of OpGen (OPGN) as of Oct 23, 2026 is 3.14 USD. In the previous year, Book Value per Share was 0.73 USD — a change of 331.63% (higher).

Book Value per Share

3.14USD

YoY

331.63%

Last updated:

Book Value per Share of OpGen is 2025 3.14 USD. Book Value per Share of OpGen was 2024 0.73 USD. It decreases by 331.63% higher compared to the previous year.

The OpGen Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
0.33 USD
Jan 1, 2019
0.42 USD
Jan 1, 2020
2.09 USD
Jan 1, 2021
4.06 USD
Jan 1, 2022
0.75 USD
Jan 1, 2023
-1.14 USD
Jan 1, 2024
0.73 USD
Jan 1, 2025
3.14 USD
The OpGen Book Value per Share history
YEARBook Value per ShareYoY
3.14USD+331.63%
0.73USD-163.84%
-1.14USD-252.61%
0.75USD-81.62%
4.06USD+94.50%
2.09USD+393.58%
0.42USD+29.76%
0.33USD+136.17%
0.14USD-55.77%
0.31USD-57.72%
0.74USD-192.88%
-0.79USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Book Value per Share of OpGen is 3.14 USD in 2025.

Book Value per Share of OpGen changed from 0.73 USD to 3.14 USD, representing a 331.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share OpGen since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — OpGen

All Key Metrics — OpGen